



GlaxoSmithKline Pharmaceuticals Limited  
GSK House, Dr. Annie Besant Road,  
Worli, Mumbai - 400 030  
Tel No: +91 22 2495 9595  
Fax No: +91 22 2495 9494  
Web: [www.gsk-india.com](http://www.gsk-india.com)  
Email: [askus@gsk.com](mailto:askus@gsk.com)

28<sup>th</sup> February 2025

To,

**BSE LIMITED**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400001

**THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (East)  
Mumbai - 400051

Dear Sir,

**Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India  
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject, we would like to inform you that the Company has received an Order dated 28<sup>th</sup> February 2025 from Karnataka Commercial Tax Department, raising total demand of Rs. 8,15,50,149 in Karnataka State. The relevant details to be disclosed are as under:

Sr no	Particulars	Details
1	Name of the authority	Deputy Commissioner of Commercial Taxes (Audit)- 2.2, DGSTO-2, Office of Deputy Commissioner, Department of Commercial Taxes, Karnataka
2	Nature and details of the action(s) taken, initiated or order(s) passed	Order dated 28 <sup>th</sup> February 2025 Tax of Rs.4,43,38,555; Interest – 3,27,77,738, and Penalty of Rs. 44,33,856 (Total demand: Rs. 8,15,50,149)
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	28 <sup>th</sup> February 2025
4	Details of violation(s) / contravention(s) committed or alleged to be committed	The officer has raised demand on account of dispute on availability of lower GST rate and also disallowed certain GST credit and raised GST demand for FY 2020-21, on account of input tax credit related issues, including difference in GST credit mismatch between Company's GST returns and details reported by suppliers in their GST returns
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	No impact on financial operations of the Company. The Company is evaluating the demand order and will take appropriate actions in due course.

Kindly take the same on the record.

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni

Vice President – Administration, Real Estate  
& Company Secretary

CIN: L24239MH1924PLC001151